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later in life, geriatric medicine is
not synonymous with palliative
medicine, and curative (but also
preventive) actions are often
possible. 4 Non-frail individuals
make up a substantial proportion of
people aged 70 years or older and
their treatment results for diseases
such as cardiovascular diseases and
cancer do not differ from those
who are younger. In pre-frail and
frail individuals, good results are
often obtainable with individualised
treatment, but this is clearly an area
where more research is needed.
If preventive actions at young
ages are increasingly successful,
we will also have healthier elderly
people in the future than we do
now; this notion is important for
the extrapolation of Goal 3.4. In
the meantime, we need geriatric
medicine for the increasing number
of people aged 70 years or older who
have chronic disorders. The proper
treatment of these elderly people is
a human rights issue, but geriatric
medicine is also effective to promote
functionality and wellbeing, giving
more life to years lived.
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Is crowdfunding a viable
source of clinical trial
research funding?
As public research grants for
randomised controlled trials (RCTs)
have diminished and become increasingly competitive, researchers
have to search for alternative funding
sources. Crowdfunding, in which
projects are funded directly from the
public through the internet, might
represent a potential source of RCT
funding.1 However, whether or not
crowdfunding campaigns for clinical
RCTs are successful is unclear.
To explore the success of research
crowdfunding campaigns, we
assessed the top online (based
on site volume) English crowdfunding websites: Gofundme,
Indiegogo, Kickstarter, Teespring,
Patreon, YouCaring, CrowdRise,
DonorsChoose, Kiva, and Giveforward.
Additionally, we examined medical
research crowdfunding websites:
Experiment, Consano, Petridish, and
Cancer Research UK. We ( AS and
JK) independently searched these
crowdfunding websites using the
following search terms: ”clinical
study”, ”randomized clinical trial”, and
”research”. We also independently
established whether a campaign
met our eligibility criteria of funding
for a clinical RCT that was led by an
academic or research institution.
A consensus process to resolve
disagreements was established.
20 campaigns met our eligibility
criteria (Cohen’s κ=0·88; appendix).
Eight (62%) of 13 completed
campaigns achieved their fundraising
goals. Unsuccessful campaigns
raised 1–6% of the funding sought.
Five (63%) of eight campaigns that
reached their funding goals were for
pilot or phase 1 studies. 19 (95%) of
20 campaigns used a ﬂexible model
(ie, researchers kept all the funds
raised) compared with a ﬁxed model
(ie, researchers kept the money only
if the target was met). The maximum

funds raised were US$3 113 000
(£2 000 000) for the Oncolytic Virus
for Patients with Neuroendocrine
Tumours study. Although details were
restricted, most research projects
seemed to have had some funding
from other sources.
Our research suggests that most
crowdfunding campaign funding
targets are achieved. Crowdfunding
might represent an eﬀective option to
rapidly raise research funds to do RCTs.
Even unsuccessful campaigns were
able to raise some funds, albeit a small
percentage of their target goal. This
strategy might be especially useful
for pilot or phase 1 studies because
funding from national public agencies
is insuﬃcient. Further research with
crowdfunding is needed to establish
strategies that maximise the likelihood
of success.
PJD has used crowdfunding (Indiegogo) to support
clinical research. AS and JK declare no competing
interests.
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Legal preparedness and
Ebola vaccines
On Dec 9, 2014, US Secretary of Health
and Human Services Sylvia Burwell
issued a declaration1 under the US
Public Readiness and Emergency
Preparedness Act to provide immunity
from legal claims in the USA related to
manufacturing, testing, development,
distribution, and administration of
three candidate Ebola vaccines except
in instances of wilful misconduct.
Although progress in combating
Ebola in west Africa has shifted
public attention away from vaccine
www.thelancet.com Vol 386 July 25, 2015

development and deployment, we
should not forget that the management of legal liabilities related to
vaccines has been an important
subject of discussion between
national governments, international
organisations, vaccine manufacturers,
and other parties who have been
engaged in the worldwide response to
the Ebola outbreak during the past year.
On the basis of previous experience
with other vaccines,2 it is reasonable
to expect that administration of
Ebola vaccines (or similar medical
countermeasures responding to
other public health emergencies
in the future) will almost certainly
result in at least some adverse
events that will give rise to legal
liabilities, for which it is not clear
what the legal and ﬁnancial process
for claims against manufacturers,
distributors, or providers might be.
Individuals experiencing such adverse
events, manufacturers, governments
receiving vaccines (eg, Guinea, Liberia,
and Sierra Leone in the context of
Ebola in west Africa), governments
supporting vaccine distribution
outside of their borders (eg, the USA,
the UK, and France in the case of
Ebola), and populations benefiting
from widespread vaccination all have
a shared interest in recognising,
understanding, and managing potential liability as eﬀectively as possible
within the framework of a global
public health response.
Legal immunities for innovators and
manufacturers of vaccines, such as
the Public Readiness and Emergency
Preparedness declaration made by
Secretary Burwell, can be part of the
solution. However, the cost of injuries
attributable to vaccines should not
simply fall on target populations. To
allow such a result to occur risks feeding
the same doubts that have thwarted
some vaccination eﬀorts in low-income
and middle-income countries across
the world. Several options are available
to the global public health community
to address potential legal liabilities
in various public health emergency
www.thelancet.com Vol 386 July 25, 2015

scenarios, including situations such
as the Ebola outbreak. Unlike many
contingencies associated with future
pandemics or similar global public
health crises that are diﬃcult—if not
impossible—to predict, creating an
improved framework for management
of legal liabilities is a preparation
that all interested stakeholders can
make before the next global health
emergency occurs.
We declare no competing interests.
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Another step change for
tobacco control in
China?
In their Editorial about tobacco
control in China (May 30, p 2122),1
the Editors of The Lancet discussed the
steps that the Chinese Government
is taking to control tobacco, which
includes the adjustment of China’s
consumption tax on the wholesale
price of cigarettes. Is increasing
tobacco taxation really another step
change for tobacco control in China?
China is the world’s largest tobacco
producer and manufacturer, and is
also home to more than 300 million
smokers who consume over one-third
of the world’s cigarettes and another
740 million people who are exposed
to passive smoking. Tobacco use in
China is causing a substantial rise
in health hazards and economic
burden, therefore comprehensive
tobacco control is clearly needed.
International experience and results of

studies consistently show that raising
taxes on tobacco is one of the most
cost-eﬀective ways to reduce tobacco
use.2 Hence, the WHO and relevant
experts have repeatedly suggested
that the Chinese Government should
control tobacco use by sharply
increasing tobacco taxes. However, for
a long time, the government has been
hesitating to use such strategies in its
bid to reduce tobacco use for some
well known reasons.3
The excise taxes on cigarettes in
China have always been very low: in
2011, taxes levied on the retail price of
cigarettes were still far from reaching
the 70% suggested by WHO. A tobacco
consumption tax was introduced
in 1994, and the tax rate increased
slightly in 1998, 2001, and 2009.
Furthermore, every time the tobacco
tax rate increased, China’s tobacco
industry subsequently increased their
subsidies to cigarette manufacturers to
oﬀset the negative eﬀect. As a result,
tobacco excise taxes could not be fully
passed on to retail prices, and the retail
prices barely changed.
On May 7, 2015, the Chinese
Ministry of Finance announced an
increment in the consumption tax
on wholesale cigarettes from 5% to
11% and each cigarette would also be
taxed ¥0·005.4 The next day, the State
Tobacco Monopoly Administration
announced a 6% increase in wholesale
cigarette prices and recommended
a 10% increase in the retail price
of each pack of cigarettes.5 Unlike
previous tobacco tax adjustments, this
increase in tobacco taxes is passed on
to retail prices, which was considered
impossible when taking into account
the unique relation between the
tobacco industry and the Chinese
Government. After May 10, 2015,
we observed that cigarette prices
had increased by about 10% in many
tobacco stores.
Most people who care about
tobacco control welcome tobacco
tax adjustment and regard it as
another step for tobacco control in
China after the announcement of a
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